J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on March 1, 2005

Papers In Press, published online ahead of print December 16, 2004
J. Lipid Res., doi:10.1194/jlr.M400400-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M400400-JLR200v1
46/3/526    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Veen, J. N.
Right arrow Articles by Kuipers, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Veen, J. N.
Right arrow Articles by Kuipers, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on October 12, 2004
Revised on November 23, 2004
Accepted on December 9, 2004

Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1

Jelske N. van der Veen, Janine K. Kruit, Rick Havinga, Julius F. W. Baller, Giovanna Chimini, Sophie Lestavel, Bart Staels, Pieter H. E. Groot, Albert K. Groen, and Folkert Kuipers

Laboratory of Pediatrics, University Hospital Groningen, Groningen 9713 GZ

Corresponding Author: j.n.van.der.veen{at}med.rug.nl

Objectives- Peroxisome proliferator-activated receptors (PPARs) control transcription of genes involved in lipid metabolism. Activation of PPARdelta may have anti-atherogenic effects through elevation of plasma HDL, theoretically promoting reverse cholesterol transport from peripheral tissues towards the liver for removal via bile and feces. Methods and results- Effects of PPARdelta activation by GW610742 were evaluated in wild-type and Abca1-deficient (Abca1-/-) mice that lack HDL. Treatment with GW610742 resulted in a ~50% increase of plasma HDL-cholesterol in wild-type mice, whereas plasma cholesterol levels remained extremely low in Abca1-/- mice. Yet, biliary cholesterol secretion rates were similar in untreated wild-type and Abca1-/- mice and unaltered upon treatment. Unexpectedly, PPARdelta activation led to enhanced fecal neutral sterol loss in both groups without any changes in intestinal Abca1, Abcg5, Abcg8 and HMG-CoA reductase expression. Moreover, GW610742 treatment resulted in a 43% reduction of fractional cholesterol absorption in wild-type mice, coinciding with a significantly reduced expression of the cholesterol absorption protein Niemann-Pick C1 Like 1 (Npc1l1) in the intestine. Conclusions- PPARdelta activation is associated with elevated plasma HDL and reduced intestinal cholesterol absorption efficiency that may be related to decreased intestinal Npc1l1 expression. Thus, PPARdelta is a promising target for drugs aimed to treat or prevent atherosclerosis.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
I. Tancevski, A. Wehinger, E. Demetz, P. Eller, K. Duwensee, J. Huber, K. Hochegger, W. Schgoer, C. Fievet, F. Stellaard, et al.
Reduced Plasma High-Density Lipoprotein Cholesterol in Hyperthyroid Mice Coincides with Decreased Hepatic Adenosine 5'-Triphosphate-Binding Cassette Transporter 1 Expression
Endocrinology, July 1, 2008; 149(7): 3708 - 3712.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T.-L. Yue, S. S. Nerurkar, W. Bao, B. M. Jucker, L. Sarov-Blat, K. Steplewski, E. H. Ohlstein, and R. N. Willette
In Vivo Activation of Peroxisome Proliferator-Activated Receptor-{delta} Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 466 - 474.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
H. M. de Vogel-van den Bosch, N. J. W. de Wit, G. J. E. J. Hooiveld, H. Vermeulen, J. N. van der Veen, S. M. Houten, F. Kuipers, M. Muller, and R. van der Meer
A cholesterol-free, high-fat diet suppresses gene expression of cholesterol transporters in murine small intestine
Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1171 - G1180.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. B. Weinglass, M. G. Kohler, E. O. Nketiah, J. Liu, W. Schmalhofer, A. Thomas, B. Williams, L. Beers, L. Smith, M. Hafey, et al.
Madin-Darby Canine Kidney II Cells: A Pharmacologically Validated System for NPC1L1-Mediated Cholesterol Uptake
Mol. Pharmacol., April 1, 2008; 73(4): 1072 - 1084.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
Y. Liu, H. van Goor, R. Havinga, J. F. W. Baller, V. W. Bloks, F. R. van der Leij, P. J. J. Sauer, F. Kuipers, G. Navis, and M. H. de Borst
Neonatal dexamethasone administration causes progressive renal damage due to induction of an early inflammatory response
Am J Physiol Renal Physiol, April 1, 2008; 294(4): F768 - F776.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
U. Riserus, D. Sprecher, T. Johnson, E. Olson, S. Hirschberg, A. Liu, Z. Fang, P. Hegde, D. Richards, L. Sarov-Blat, et al.
Activation of Peroxisome Proliferator-Activated Receptor (PPAR){delta} Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men
Diabetes, February 1, 2008; 57(2): 332 - 339.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. A. Valasek, S. L. Clarke, and J. J. Repa
Fenofibrate reduces intestinal cholesterol absorption via PPAR{alpha}-dependent modulation of NPC1L1 expression in mouse
J. Lipid Res., December 1, 2007; 48(12): 2725 - 2735.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. E. Hollingshead, R. L. Killins, M. G. Borland, E. E. Girroir, A. N. Billin, T. M. Willson, A. K. Sharma, S. Amin, F. J. Gonzalez, and J. M. Peters
Peroxisome proliferator-activated receptor- /{delta} (PPAR /{delta}) ligands do not potentiate growth of human cancer cell lines
Carcinogenesis, December 1, 2007; 28(12): 2641 - 2649.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. M. Jucker, D. Yang, W. M. Casey, A. R. Olzinski, C. Williams, S. C. Lenhard, J. J. Legos, C. T. Hawk, S. K. Sarkar, and S. J. Newsholme
Selective PPAR{delta} agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1256 - E1264.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Schupp, J. C. Curtin, R. J. Kim, A. N. Billin, and M. A. Lazar
A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-{gamma} Activity
Mol. Pharmacol., May 1, 2007; 71(5): 1251 - 1257.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. N. van der Veen, R. Havinga, V. W. Bloks, A. K. Groen, and F. Kuipers
Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor {alpha}
J. Lipid Res., February 1, 2007; 48(2): 337 - 347.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. N. Mathur, K. R. Watt, and F. J. Field
Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid
J. Lipid Res., February 1, 2007; 48(2): 395 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. L. Sprecher, C. Massien, G. Pearce, A. N. Billin, I. Perlstein, T. M. Willson, D. G. Hassall, N. Ancellin, S. D. Patterson, D. C. Lobe, et al.
Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor {delta} Agonist
Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 359 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
W. A. Alrefai, F. Annaba, Z. Sarwar, A. Dwivedi, S. Saksena, A. Singla, P. K. Dudeja, and R. K. Gill
Modulation of human Niemann-Pick C1-like 1 gene expression by sterol: role of sterol regulatory element binding protein 2
Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G369 - G376.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Lalloyer, C. Fievet, S. Lestavel, G. Torpier, J. van der Veen, V. Touche, S. Bultel, S. Yous, F. Kuipers, R. Paumelle, et al.
The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia
Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2731 - 2737.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
T. Plosch, J. N. van der Veen, R. Havinga, N. C. A. Huijkman, V. W. Bloks, and F. Kuipers
Abcg5/Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice
Am J Physiol Gastrointest Liver Physiol, September 1, 2006; 291(3): G414 - G423.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
T. Plosch, J. K. Kruit, V. W. Bloks, N. C. A. Huijkman, R. Havinga, G. S. M. J. E. Duchateau, Y. Lin, and F. Kuipers
Reduction of Cholesterol Absorption by Dietary Plant Sterols and Stanols in Mice Is Independent of the Abcg5/8 Transporter
J. Nutr., August 1, 2006; 136(8): 2135 - 2140.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.